The Virtus Dividend, Interest & Premium Strategy Fund completed a tender offer accepting 23.2 million shares, representing 25% of its outstanding shares, at $15.9192 per share, close to its net asset value. Although 28.8 million shares were tendered, only about 31% of total shares participated, below the anticipated 50%, partly due to large holdings by Saba Capital. Investors who tendered shares saw a modest gain compared to losses for those who held their shares. The fund's discount widened after the offer expired, indicating market reaction to the tender results. This event highlights investor behavior and pricing dynamics in closed-end funds.
The NFJ tender offer results provide context for market activity on Pluang. For readers following US stocks, here is Pluang's market snapshot as of Oct 21, 2026 00:31 WIB: out of 150 priced US stocks, 112 rose and 38 fell. Notably, Sea Limited (SE) dropped 8.23% with a 23% sell order activity, contrasting with BlackBerry Limited (BB) and Xpeng Inc (XPEV), which rose 7.48% and 7.38% respectively, with BB seeing 69% buy orders and XPEV balanced at 50% sell/buy. Typical hold times ranged from 51 to 103 days across these assets.
Moody's is expected to report Q3 2026 earnings of around $4.25 per share on revenue near $2.08 billion, driven by steady demand for credit ratings and growth in Moody's Analytics, especially from recurring subscriptions and AI tools. While Moody's In...
Raymond James increased its price target for Rapport Therapeutics to $86 following positive Phase 2 trial results of RAP-219, a drug treating acute bipolar mania. The trial showed statistically significant improvement in patients and a favorable safe...
Heartland Express reported a third-quarter 2026 revenue decline of 8.7% to $179.5 million, missing analyst estimates. Despite lower revenue, the company returned to profitability with a net income of $1.0 million, compared to a loss last year. The op...
Catholic Medical Mission Board (CMMB) held a ribbon-cutting ceremony for its new Distribution Center at the Brethren Service Center in New Windsor, Maryland. This move enhances CMMB's Access to Medicines Program by expanding operational capacity and ...
Piper Sandler upgraded Myriad Genetics from Underweight to Neutral and set a $5.00 price target after the company agreed to sell its prenatal health testing business to Labcorp for $210 million in cash. This sale includes several prenatal tests and i...
